Andere talen Achilles Therapeutics plc

Aandelen

ACHL

US00449L1026

Biotechnologie & Medisch Onderzoek

Vertraagde tijd Nasdaq Andere beurzen 21:00:00 20-03-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,480 ^USD	+0,68%		-.--%	+29,82%

05/02	Syncona portefeuillebedrijf Achilles Therapeutics gaat over tot vrijwillige liquidatie	MT
04/02	Sergio Quezada stapt op als Chief Scientific Officer van Achilles Therapeutics plc	CI

Andere talen

Achilles Therapeutics plc(NasdaqCM:ACHL) dropped from NASDAQ Composite Index	20/03
Achilles Therapeutics Announces Voluntary Nasdaq Delisting and SEC Deregistration	28/02
Syncona Portfolio Company Achilles Therapeutics to Pursue Voluntary Liquidation	05/02
Achilles Therapeutics plc Announces Principal Executive Office Changes	04/02
Sergio Quezada Steps Down as Chief Scientific Officer of the Achilles Therapeutics plc	04/02
Achilles Therapeutics plc Announces Board Resignations	06/01
Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca	27/12
Stocks seen down as holiday sales stabilise	27/12
Achilles Therapeutics : Announces Sale of Technology Assets to AstraZeneca Form 6 K	26/12
Achilles Therapeutics Sells Technology Assets to AstraZeneca for $12 Million	24/12
Achilles Therapeutics Sells Technology Assets to AstraZeneca for $12 Million, Concluding Strategic Review; Shares Up	24/12
Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca	24/12
AstraZeneca PLC acquired Technology Assets of Achilles Therapeutics plc for $12 million.	24/12
Achilles Therapeutics : Information Contained in this Report on Form 6 K Form 6 K	02/12
Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market	19/11
Achilles Therapeutics : Reports Third Quarter 2024 Financial Results Form 6 K	14/11
Achilles Therapeutics Reports Third Quarter 2024 Financial Results	14/11
Achilles Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	14/11
TIL Summit – Boston – October 2024: Targeting Clonal Neoantigens with Precision Cell Therapies	05/11
Scancell Holdings plc Appoints Dr Phil L'huillier as Board Member, Effective 18 November 2024	22-10-24
European Equities Traded in the US as American Depositary Receipts Edge Higher in Monday Trading	23-09-24
European Equities Traded in the US as American Depositary Receipts Decrease Friday	20-09-24
Syncona notes investee Achilles' plan to close its lead program	19-09-24
Achilles Therapeutics Discontinues cNeT Program and Closes Early-to-Mid Stage Studies For Cancer Treatment	19-09-24
Achilles Therapeutics Announces Strategic Update	19-09-24

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Achilles Therapeutics plc

Aandelen

ACHL

US00449L1026

Biotechnologie & Medisch Onderzoek

Andere talen

Filters